Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment trastuzumab
Drugstatus Approved, Investigational
Drugbank ID DB00072<U+00A0> (BTD00098, BIOD00098)
Checkpoints NA
Signature Type Gene
Signature MHC-II
Official Symbol NA
Mode of action TRAN_R_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Patients who responded to single-agent trastuzumab had basal tumour biopsies that were enriched in immune pathways, particularly the MHC-II metagene. One cycle of trastuzumab modulated the expression levels of MHC-II genes, which increased in patients who had a complete response on treatment with trastuzumab and chemotherapy. Trastuzumab increased the MHC-II-positive cell population, primarily macrophages, only in the tumour microenvironment of responsive mice.;C+K+(clinical (C) and Ki67 (K)) tumours expressed higher levels of the MHC-II metagene (p = 0.0696) than other tumours . The lymphocyte-specific kinase (LCK) and haematopoietic cell kinase (HCK) metagenes followed the same trend, albeit insignificantly
PMID 30478407
Title Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit